Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of response to kinase inhibitors based on tumor phosphoproteomic profiles in advanced renal cell cancer
2011-006009-85Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sunitinib, sorafenib, pazopanib, axitinib and everolimus in renal cell carcinoma (RCC) (5 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Prediction accuracy of the phosphoproteomic classifier. Started May 2012; status: active.
02
Drugs
sunitinibsorafenibpazopanibaxitinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2011-006009-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006009-85.